# Pulmatrix, Inc.: overview

PULM · Nasdaq · CIK 1574235 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pulm.md) · [Financials](/companies/pulm/financials.md) · [Filings](/companies/pulm/filings.md) · [Insiders](/companies/pulm/insiders.md)

Latest reported revenue: [$3.0k](/filings/0001493152-26-028902.md) for Q4 FY2024, three months to 2024-12-31, from the 10-K/A filed Jun 16, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-028902).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [366](/filings/0001493152-25-018256.md) | [3.0 d](/filings/0001493152-26-028902.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(726.0%)](/filings/0001493152-25-018256.md) | [(65066.7%) d](/filings/0001493152-26-028902.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [(706.8%)](/filings/0001493152-25-018256.md) | [(66200.0%) d](/filings/0001493152-26-028902.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.71)](/filings/0001493152-25-018256.md) | not reported | [(0.50)](/filings/0001493152-26-023368.md) | [(0.42)](/filings/0001493152-26-037594.md) | [(0.24)](/filings/0001493152-25-018256.md) | not reported | [(0.32)](/filings/0001493152-26-023368.md) | [(0.29)](/filings/0001493152-26-037594.md) |
| Free cash flow | $k | [(3,059) d](/filings/0001493152-25-018256.md) | [(1,261) d](/filings/0001493152-26-028902.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [5.2](/filings/0001493152-23-009609.md) | [6.1](/filings/0001493152-24-011630.md) | [7.3](/filings/0001493152-25-011084.md) | [7.8](/filings/0001493152-26-028902.md) | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(390.2%)](/filings/0001493152-23-009609.md) | [(312.1%)](/filings/0001493152-24-011630.md) | [(202.0%)](/filings/0001493152-25-011084.md) | [(125.1%)](/filings/0001493152-26-028902.md) | not reported |
| Net margin | % | [(390.2%)](/filings/0001493152-23-009609.md) | [(310.3%)](/filings/0001493152-24-011630.md) | [(193.5%)](/filings/0001493152-25-011084.md) | [(122.5%)](/filings/0001493152-26-028902.md) | not reported |
| Diluted EPS | $ per share | [(8.63)](/filings/0001493152-22-007957.md) | [(5.46)](/filings/0001493152-24-011630.md) | [(3.87)](/filings/0001493152-25-011084.md) | [(2.62)](/filings/0001493152-26-028902.md) | [(1.41)](/filings/0001493152-26-028902.md) |
| Free cash flow | $m | [(19.9)](/filings/0001493152-23-009609.md) | [(19.4)](/filings/0001493152-24-011630.md) | [(16.7)](/filings/0001493152-25-011084.md) | [(11.1)](/filings/0001493152-26-028902.md) | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pulm/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2015-06-17 | [Oculus Innovative Sciences, Inc.](/insiders/1367083.md) | 10% owner | Sale (S) | 922,500 | $2.75 | $2.5m | [Form 4](/filings/0001019687-15-002493.md) |
| 2015-06-16 | [Oculus Innovative Sciences, Inc.](/insiders/1367083.md) | 10% owner | Sale (S) | 727,500 | $2.75 | $2.0m | [Form 4](/filings/0001019687-15-002493.md) |
| 2015-03-23 | [Oculus Innovative Sciences, Inc.](/insiders/1367083.md) | 10% owner | Sale (S) | 350,000 | $2.75 | $962.5k | [Form 4](/filings/0001019687-15-001080.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $208.6k | 122,698 |  | Added +13,550 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $93.3k | 54,899 |  | Unchanged |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $56.6k | 33,299 |  | Reduced −11,330 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $54.9k | 32,294 |  | Reduced −1,300 |
| [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $53.2k | 31,285 |  | Added +1,200 |
| [Shay Capital LLC](/funds/1723643.md) | 2026-06-30 | $32.1k | 18,857 |  | New +18,857 |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $25.0k | 14,715 |  | Unchanged |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $23.7k | 13,945 |  | Unchanged |
| [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $20.4k | 11,991 |  | Reduced −1,678 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $875 | 515 |  | Added +492 |

## Recent filings

[All 645 filings](/companies/pulm/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-27 | 09:00 ET | [8-K](/filings/0001493152-26-048644.md) | 5.07 Shareholder vote results | 0001493152-26-048644 |
| 2026-08-13 | 08:20 ET | [10-Q](/filings/0001493152-26-037594.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037594 |
| 2026-08-13 | 08:15 ET | [8-K](/filings/0001493152-26-037592.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-037592 |
| 2026-06-16 | 16:36 ET | [10-K/A](/filings/0001493152-26-028902.md) | Annual report, amended, period 2025-12-31 | 0001493152-26-028902 |
| 2026-05-15 | 08:20 ET | [10-Q](/filings/0001493152-26-023368.md) | Quarterly report, period 2026-03-31 | 0001493152-26-023368 |
| 2026-05-15 | 08:20 ET | [8-K](/filings/0001493152-26-023367.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-023367 |
| 2026-04-22 | 16:24 ET | [SCHEDULE 13D](/filings/0001104659-26-046851.md) | Ownership report, active investor | 0001104659-26-046851 |
| 2026-04-21 | 08:00 ET | [8-K](/filings/0001493152-26-018202.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-018202 |
| 2026-03-27 | 17:16 ET | [8-K](/filings/0001493152-26-013266.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.01 Change in control; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-013266 |
| 2026-03-02 | 08:00 ET | [8-K](/filings/0001493152-26-008449.md) | 1.02 Termination of a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-008449 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-008130.md), filed Feb 26, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1574235
- Tickers: PULM
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 07:25 ET. No prices; not investment advice.